STANFORD, Calif. – April 24, 2024 – In a discovery poised to fundamentally reshape our understanding of cancer immunology, scientists have unveiled a surprising, critical role for a protein identified nearly four decades ago. Erythropoietin (EPO), long celebrated for its ability to stimulate red blood cell production, has now been unmasked as a potent suppressor of the immune system’s response to cancer, a finding published today in the prestigious journal Science.
The groundbreaking research, led by Dr. Edgar Engleman and Dr. David Kung-Chun Chiu at Stanford University, demonstrates that blocking EPO’s activity can transform previously "cold" – or immune-resistant – liver tumors in mice into "hot" tumors, teeming with an army of cancer-fighting immune cells. When this intervention was combined with existing immunotherapy designed to further activate these immune cells, the results were dramatic: complete regression of existing liver tumors in most mice, with treated animals living for the entire duration of the experiment. In stark contrast, control animals succumbed to the disease within weeks.
"This is a fundamental breakthrough in our understanding of how the immune system is turned off and on in cancer," declared Dr. Engleman, a professor of pathology and medicine and the senior author of the research. His enthusiasm is palpable: "I could not be more excited about this discovery, and I hope treatments that target the mechanism we uncovered will quickly move forward to human trials."
The implications extend far beyond liver cancer. Strong indications suggest that EPO plays a similar immunosuppressive role in a wide array of human cancers, promising a new therapeutic avenue for many patients who currently have limited options.
The Core Revelation: EPO’s Dual Identity
At its heart, this discovery reveals a startling dual identity for erythropoietin. For decades, EPO has been a cornerstone of medical treatment, particularly for anemia, where its ability to stimulate the bone marrow to produce red blood cells has saved countless lives. It’s a hormone intrinsically linked to vitality and recovery, a biological signal for cellular proliferation and oxygen delivery.
However, the Stanford team’s meticulously conducted research now paints a far more complex picture. They’ve discovered that EPO, when produced by cancer cells, acts as a sophisticated molecular saboteur, actively dampening the body’s natural defenses against malignancy. This newly identified role positions EPO not merely as a growth factor, but as a critical modulator of the tumor microenvironment, capable of orchestrating immune evasion.
The transformation of "cold" tumors into "hot" ones is particularly significant. "Cold" tumors are characterized by a sparse infiltration of immune cells, especially T cells, rendering them largely unresponsive to immunotherapies that rely on activating these cells. By blocking EPO, the researchers effectively removed a critical barrier, allowing immune cells to flood into the tumor and launch an attack. This "reheating" of the tumor microenvironment then synergized powerfully with anti-PD-1 immunotherapy, which works by lifting the "brakes" off T cells, enabling them to recognize and destroy cancer cells more effectively. The combination proved to be a potent one, leading to the unprecedented complete tumor regressions and long-term survival observed in the mouse models. This synergistic effect offers a beacon of hope for patients whose cancers are currently resistant to even the most advanced immunotherapies.
A Journey Through Time: EPO’s Tumultuous History with Cancer
The current breakthrough is not EPO’s first encounter with the complex world of oncology. In fact, its history with cancer has been fraught with paradox and caution, a narrative that lends deeper context and urgency to the current findings.
From Red Blood Cells to Cancer Accelerator: The Early Years
Erythropoietin’s primary function was first identified nearly 40 years ago, establishing its reputation as the quintessential red blood cell growth factor. Its therapeutic application quickly followed, providing a vital treatment for anemia, particularly in patients with kidney disease or those undergoing chemotherapy. For a time, it seemed like a benevolent biological agent, a straightforward solution to a common medical problem.
However, a shadow began to emerge over EPO’s therapeutic profile in the early 2000s. Clinical trials investigating the use of EPO to treat anemia in cancer patients, particularly those undergoing chemotherapy, yielded disturbing results. Instead of simply alleviating anemia, evidence began to mount that exogenous EPO administration could, in some cases, accelerate tumor growth and even shorten overall survival.
"Research from more than a decade ago has shown that giving EPO to cancer patients with anemia to stimulate red blood cell formation accelerates the growth of the tumor," Dr. Engleman recounted, highlighting the early warning signs. This connection was so striking and concerning that in 2007, the U.S. Food and Drug Administration (FDA) mandated a black box warning label on EPO-containing drugs, cautioning against their use in people with cancers outside of very specific circumstances. This was a significant regulatory step, underscoring the serious nature of the observed adverse effects.
Further epidemiological and correlative studies reinforced this troubling link. Researchers observed a clear and often grim correlation between patient prognosis and the levels of naturally occurring EPO and its receptor (EPOR) within tumors. "Those old reports showed clearly that the more EPO or EPOR there was in tumors, the worse off the patients were," Engleman noted. The mystery deepened: how could a protein vital for blood production also be a harbinger of poor cancer outcomes? The biological mechanisms underlying this observed acceleration of tumor growth, however, remained largely elusive and were primarily attributed to direct effects on cancer cell proliferation.
The Missing Link: Unraveling the Immunosuppressive Role
Despite the strong correlations and the FDA warnings, the precise connection between EPO and the immune system’s interaction with cancer remained an unexplored frontier. The prevailing dogma was so entrenched – EPO as a red blood cell growth factor – that few considered a broader, more intricate role, particularly one involving immune modulation.
"But the connection between EPO and cancer immunity was never made until now," Engleman explained, emphasizing the novelty of the current discovery. "In fact, it took a long time and a lot of experiments to convince us that EPO plays a fundamental role in blocking the immune response to cancer, because EPO is so well established as a red blood cell growth factor." This admission speaks to the inherent difficulty in challenging long-held scientific paradigms and the perseverance required to pursue unexpected findings.
The intellectual journey to this breakthrough began with Dr. David Kung-Chun Chiu, the lead author of the study. Chiu embarked on a meticulous endeavor to develop and study advanced genome editing techniques. His goal was to create sophisticated mouse models of liver cancer that accurately recapitulated the specific mutations, histological features, and responses to approved therapies observed in various subtypes of human liver cancers. These models were crucial for a detailed mechanistic investigation. Tumor formation in these mice was induced either by injecting a combination of DNA encoding proteins associated with liver cancer into the animals’ tail veins or by directly implanting liver cancer cells into the animals’ livers, allowing for precise control and observation of tumor development and progression. This foundational work provided the robust experimental platform necessary to uncover EPO’s hidden role.
Deconstructing the Mechanism: How EPO Silences the Immune System
The Stanford team’s investigation delved deep into the intricate cellular and molecular pathways that govern cancer’s interaction with the immune system, revealing a sophisticated mechanism by which EPO exerts its immunosuppressive effects.
Mouse Models: A Window into Liver Cancer Dynamics
Dr. Chiu’s carefully engineered mouse models proved invaluable. These models allowed the researchers to observe how different genetic mutations influenced tumor development and, crucially, how these tumors responded to therapeutic interventions. The precision of these models, mirroring the heterogeneity of human liver cancers, was key to identifying subtle yet profound biological shifts.
Initially, the researchers were focused on the impact of a common immunotherapy targeting a molecule called PD-1. PD-1 is expressed on the surface of immune cells, particularly T cells. Cancer cells often exploit the PD-1 pathway by expressing its ligand, PD-L1, which binds to PD-1 and effectively "turns off" the T cells, allowing the tumor to evade immune surveillance. Anti-PD-1 therapies, such as pembrolizumab (marketed commercially as Keytruda), work by blocking this interaction, thereby reactivating T cells to attack the cancer. These therapies have revolutionized the treatment landscape for certain cancers, including melanoma, Hodgkin’s lymphoma, and some types of lung cancer, transforming patient outcomes from grim prognoses to long-term survival for many.
However, a significant challenge remains: a large majority of tumors, encompassing many liver, pancreas, colon, breast, and prostate cancers, exhibit inherent resistance to anti-PD-1 treatment. This resistance often stems from these tumors being "cold," meaning they have a very limited presence of T cells within their microenvironment, making them immune-privileged and unresponsive to therapies that aim to activate T cells.
The PD-1 Conundrum: Why Immunotherapy Fails Some Cancers
The researchers’ observations in their mouse models mirrored this clinical reality. They found that specific combinations of mutations led to the development of liver tumors that were largely ignored by the immune system. These were the "cold" tumors, characterized by a dearth of T cells. Consequently, these tumors did not shrink when the animals were treated with anti-PD-1, reflecting the clinical resistance seen in human patients.
In stark contrast, other genetic mutations led to "hot" or "inflamed" tumors. These tumors were replete with T cells and were highly sensitive to anti-PD-1 treatment, which effectively triggered the T cells to launch a robust attack against the cancer, leading to significant tumor regression. This dichotomy between cold and hot tumors provided the critical context for the unexpected discovery that followed.
Hypoxia, EPO, and the Immunosuppressive Switch
The pivotal moment arrived with an unexpected observation: the cold tumors, those resistant to immunotherapy, displayed significantly elevated levels of EPO compared with their hot counterparts. This striking correlation immediately raised questions about EPO’s role beyond its established function.
The researchers soon connected this increase in EPO to the prevalent condition of hypoxia – an oxygen-poor microenvironment – within these cold tumors. Hypoxia is a common feature of rapidly growing tumors, as their demand for oxygen outstrips the supply from nascent blood vessels. In response to low oxygen levels, cancer cells, much like other cells in the body, induce the production of various proteins. It became clear that this hypoxic stress was ramping up the production of EPO within the tumor cells themselves, an adaptive response to create more red blood cells to combat the perceived oxygen deficit.
"Hypoxia in tumors has been studied for decades," Engleman acknowledged, reflecting on the scientific blind spot. "It just didn’t dawn on anyone, including me, that EPO could be doing anything in this context other than serving as a red blood cell growth factor." This statement underscores how deeply ingrained the conventional understanding of EPO was, making the current discovery all the more significant.
To validate their murine observations, the researchers turned to existing human cancer databases. They confirmed that elevated levels of EPO are indeed correlated with poorer survival rates in patients with a variety of cancers, including those of the liver, kidney, breast, colon, and skin. This strong translational link bolstered the confidence in their mouse model findings.
Experimental Validation: Manipulating EPO and Immune Response
With a strong correlation established, the team proceeded to conduct elegant experiments to prove causation. They genetically tinkered with the ability of tumor cells to produce EPO, observing the profound consequences for the immune response.
In a crucial set of experiments, mutations that had previously led to the development of cold, immune-resistant tumors now caused the formation of hot, immune-responsive tumors when the tumor cells were modified to be unable to make EPO. Conversely, hot tumors that had previously been successfully eradicated by the immune system thrived and evaded immune destruction when they were engineered to produce elevated levels of EPO. These reciprocal experiments provided compelling evidence that EPO was not merely correlated with immune suppression, but was actively driving it.
Further exhaustive research painstakingly elucidated the precise cellular and molecular crosstalk. They discovered that in cold tumors, the tumor cells themselves are the primary producers and secretors of EPO. This secreted EPO then binds to specific receptors located on the surface of immune cells called macrophages, which are abundant in the tumor microenvironment. Upon binding, EPO acts as a signaling molecule, inducing a phenotypic switch in these macrophages. Instead of acting as pro-inflammatory, tumor-killing cells, these macrophages adopt an immunosuppressive role. In this altered state, they actively "shoo away" cancer-killing T cells, preventing their infiltration into the tumor, and simultaneously dampen the activity of any T cells that do manage to enter the tumor microenvironment. This detailed mechanism reveals EPO as a master orchestrator of an immunosuppressive cascade.
The Synergistic Power: EPO Blockade and Anti-PD-1
The ultimate validation of EPO’s role and the potential for therapeutic intervention came from experiments studying the combinatorial effect of simultaneously blocking the EPO signaling pathway and the anti-PD-1 pathway. These experiments were designed to test whether targeting EPO could "reprogram" the tumor microenvironment to become sensitive to existing immunotherapies.
The results were unequivocally powerful. In experiments involving mice with cold liver tumors, animals treated with either a control substance or anti-PD-1 monotherapy showed dismal survival, with none living more than eight weeks after tumor induction. This reiterated the inherent resistance of cold tumors to current immunotherapy.
However, a dramatic shift occurred when the EPO signaling pathway was disrupted. In mice whose macrophages were genetically engineered to be unable to make the EPO receptor – effectively blocking EPO’s ability to signal to these key immune cells – 40% lived for 18 weeks after tumor induction, at which point the experiment was terminated. This alone showed a significant improvement in survival, demonstrating the therapeutic potential of targeting EPO.
The most striking outcome, however, emerged when anti-PD-1 treatment was administered to mice that also lacked the EPO receptor on their macrophages. In this combined therapeutic approach, all animals lived for the duration of the experiment, demonstrating complete and sustained tumor regression.
"It’s simple," Engleman stated with conviction, summarizing the profound implications. "If you remove this EPO signaling, either by lowering the hormone levels or by blocking the receptors on the macrophages, you don’t just get a reduction in tumor growth, you get tumor regression along with sensitivity to anti-PD-1 treatment." This clarity of outcome underscores the potential to convert previously untreatable cancers into responsive ones.
Expert Perspectives and Future Trajectories
The discovery has been met with significant excitement within the scientific community, particularly from the lead researchers who have dedicated years to this complex puzzle.
A "Fundamental Breakthrough" with Broad Implications
Dr. Engleman’s declaration of a "fundamental breakthrough" is not hyperbole. It signifies a paradigm shift in how EPO is viewed in the context of cancer. From a benign red blood cell stimulator, and later a cautious cancer accelerator, it is now understood as a sophisticated immune modulator. This expanded understanding opens up new avenues for therapeutic intervention that were previously unimagined.
The potential applicability of these findings is vast. While the initial work was completed in mouse models of liver cancer, the strong indications from human cancer databases suggest that EPO plays a similar immunosuppressive role in "many types of human cancers." This includes common and often resistant malignancies such as kidney, breast, colon, and skin cancers. This broad applicability suggests that therapies derived from this discovery could benefit a significant proportion of cancer patients globally.
The shift in understanding EPO from merely a red blood cell factor to a critical immune checkpoint represents a significant intellectual leap. It highlights the complex interplay between different physiological systems and how processes designed for normal bodily function can be hijacked and repurposed by cancer to evade detection and destruction.
Charting the Path to Human Trials
With the robust preclinical data in hand, Dr. Engleman and his colleagues are now actively designing treatments targeting EPO signaling in human cancers. The journey from mouse models to human trials is often long and challenging, but the clarity and potency of these results provide a strong impetus for rapid translation.
Two primary therapeutic approaches are currently under consideration:
-
Non-specific EPO targeting: This approach would aim to lower overall EPO levels or block EPO’s activity systemically. Dr. Engleman acknowledges that non-specifically targeting the EPO protein could lead to side effects, most notably anemia, given EPO’s crucial role in red blood cell production. However, he speculates that "this might be an acceptable trade-off for an effective cancer therapy," particularly for patients with aggressive, resistant cancers where other options have failed. The severity of the cancer might justify the management of anemia as a treatable side effect.
-
Selective blockade of EPO receptors on macrophages: This more targeted approach aims to specifically interfere with EPO signaling only on the immune cells (macrophages) within the tumor microenvironment, thereby minimizing systemic side effects. By leaving EPO’s function in red blood cell production intact, this strategy could offer a more precise and less toxic therapeutic option. Developing drugs that can selectively target EPO receptors on macrophages while sparing other cells will be a key challenge, but one with high potential rewards.
Dr. Engleman remains remarkably optimistic about the future impact of this work. "I continue to be amazed by this finding," he shared. While acknowledging that "not every tumor is going to respond in the same way," he firmly believes that "this discovery will lead to powerful new cancer therapies." The prospect of converting "cold" tumors into "hot" ones, thereby sensitizing them to existing immunotherapies, represents a profound advance that could dramatically improve patient outcomes.
The research was a collaborative effort, with contributions from scientists at the New York Blood Center and the pharmaceutical company ImmunEdge Inc., highlighting the multidisciplinary nature of cutting-edge cancer research. The study received crucial financial support from the National Institutes of Health through several grants (R01CA262361, P01CA244114, U54CA2745115, and P01HL149626).
It is important to note that both Dr. Chiu and Dr. Engleman have affiliations with ImmunEdge Inc., with Dr. Chiu as a cofounder and Dr. Engleman as a founder, shareholder, and board member. Furthermore, both are Stanford-affiliated inventors of a patent application (PCT/US2023/063997) entitled "EPO receptor agonists and antagonists," underscoring the direct translational potential and commercial interest in their findings. These disclosures are standard practice in scientific publications and highlight the close ties between academic discovery and the development of new therapeutic agents.
This monumental discovery promises to redefine a decades-old protein and unleash new strategies in the ongoing fight against cancer, offering a renewed sense of hope for patients facing some of the most challenging forms of the disease.
About the Author
